Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11035529 | 1.00 | ALDH1A1 (0.34) | ALDH1A1EPHX1 | |
| SCHEMBL14241092 | 1.00 | ALDH1A1 (0.34) | ALDH1A1EPHX1 | |
| SCHEMBL829693 | 1.00 | ALDH1A1 (0.34) | ALDH1A1EPHX1 | |
| SCHEMBL1061060 | 0.97 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL29992490 | 0.91 | ALDH1A1 (0.32) | ALDH1A1EPHX1 | |
| SCHEMBL889477 | 0.90 | — | — | |
| SCHEMBL10081554 | 0.88 | ENPP2 (0.35) | — | |
| SCHEMBL7795606 | 0.87 | ALDH1A1 (0.42) | ALDH1A1EPHX1 | |
| SCHEMBL3807307 | 0.87 | ALDH1A1 (0.42) | ALDH1A1EPHX1 | |
| SCHEMBL6923843 | 0.80 | MEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149829-B | Preparation method of bipidedic acid | 苏州立新制药有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-113149829-A | Preparation method of bipidedic acid | 苏州立新制药有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122029163-A | Chemical for targeting chromatin remodeling complexes and uses thereof | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | disclosed |
| EP-4626554-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025090809-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025075967-A1 | CHEMICAL MATTERS FOR TARGETING CHROMATIN REMODELING COMPLEXES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4511128-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12195465-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-119095849-A | Macrocyclic heterocycles and uses thereof | 金橘生物科技公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168349-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
| EP-0873311-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-10-28 | — | — | EP | disclosed |
| EP-0873310-A1 | DIPHENYL PYRIDYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-10-28 | — | — | EP | disclosed |
| US-5710160-A | PHOSPHODIESTERASE IV INHIBITORS FOR TREATMENT OF ASTHMA BY RAISING LEVELS OF CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| US-5710170-A | Tri-aryl ethane derivatives as PDE IV inhibitors | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| WO-1997022585-A1 | DIPHENYL PYRIDYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-06-26 | — | — | WO | disclosed |
| WO-1997022586-A1 | TRI-ARYL ETHANE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | ALDH1A1 3584/4885EPHX1 4583/4885 |
| US-12195465-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | ALDH1A1 4341/4885EPHX1 4387/4885 |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | ALDH1A1 1085/4885EPHX1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.